Qualifies· moderateTIK-E012
Systematic review of LSA pharmacology: psychoactive, weaker than LSD, messy in humans
- what the source states
- The 2025 systematic review characterizes lysergic acid amide (LSA) as a psychoactive LSD analog with documented hallucinations and euphoria, alongside prominent adverse outcomes in the human literature — nausea, autonomic and vegetative effects, anxiety, and occasional severe psychiatric or cardiovascular events — and substantially lower potency than LSD.
- what we infer
- Keeps the pharmacological gap open and honest: "LSA was produced" does not become "an LSD-like mystical experience would predictably result." Four separable propositions — LSA reaches the brain, is psychoactive, can hallucinate, and reliably yields a profound positive experience at achievable doses — have support that stops at the third.
- limitations
- Human data are dominated by morning-glory-seed exposures, not lye-processed ergot extracts; the reconstructed preparation itself has never been profiled (TIK-R003).